E
EIT Pharma
Therapies for serious and life-threatening viral diseases.
About EIT Pharma
EIT Pharma, Inc. is a Kirkland, Washington-based biotechnology company focused on developing therapies for serious viral and infectious diseases with significant unmet medical need. Its lead candidate is lonafarnib (Jitixib), a first-in-class oral farnesyltransferase inhibitor being developed for chronic hepatitis D (CHD), supported by the Phase 3 D-LIVR study — the largest clinical trial conducted to date in CHD. Lonafarnib has received FDA Breakthrough Therapy, Fast Track and Orphan Drug designations, and its New Drug Application was accepted for FDA review in August 2026. The company is also advancing peginterferon lambda-1a (lambda) for chronic hepatitis D and severe acute viral respiratory tract infections.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- Kirkland, United States
- Employees
- 6
- Open positions
- None listed
- Dealroom signal
- 25.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Drug Development, Infections and Infectious Diseases, Chronic Disease, Woman Founder
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Aug 2026 | $35M | $140M | Good Ventures · Propel Bio Partners | ↗ |
Growth signals
Latest recorded traffic for EIT Pharma is 1.8K monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
| Company | Headquarters | Status | Employees | Total funding | Valuation |
|---|---|---|---|---|---|
 R1 TherapeuticsPharmaceutical therapies targeting neurological, metabolic and infectious conditions |
Temecula, United States | Operational | 16 | $78M | $310M |
 AkigaiRepurposed oncology drugs for neuropathic pain treatment |
Oslo, Norway | Operational | |||
 IstessoDeveloping adaptive tissue-repair drugs for chronic diseases |
London, United Kingdom | Operational | |||
 AbivaxStimulation of the immune system for the complete elimination of viral diseases using its unique antiviral platform technologies |
Paris, France | Operational | |||
 Dimicare BiotechPrecision antibiotics for multidrug-resistant pathogens. |
Nice, France | Operational | |||
 AllRock BioTherapies for rare cardiopulmonary and fibrotic diseases |
Natick, United States | Operational | |||
 Otsuka PharmaceuticalGlobal leader in pharmaceuticals and health-enhancing nutraceutical products |
Tokyo, Japan | Operational | |||
 Pharmotech SAPhytopharma R&D for antibiotic-resistant bacteria applications. |
Plan-les-Ouates, Switzerland | Operational |
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Propel Bio Partners
Good Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about EIT Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See EIT Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.